Nothing Special   »   [go: up one dir, main page]

WO2012156473A3 - A set of micrornas as markers and targets in cancer and immune system related diseases, methods for their application and a kit - Google Patents

A set of micrornas as markers and targets in cancer and immune system related diseases, methods for their application and a kit Download PDF

Info

Publication number
WO2012156473A3
WO2012156473A3 PCT/EP2012/059186 EP2012059186W WO2012156473A3 WO 2012156473 A3 WO2012156473 A3 WO 2012156473A3 EP 2012059186 W EP2012059186 W EP 2012059186W WO 2012156473 A3 WO2012156473 A3 WO 2012156473A3
Authority
WO
WIPO (PCT)
Prior art keywords
targets
micrornas
markers
cancer
immune system
Prior art date
Application number
PCT/EP2012/059186
Other languages
French (fr)
Other versions
WO2012156473A2 (en
Inventor
Ana REBANE
Liina TSEREL
Toomas RUNNEL
Kai KISAND
Maire PIHLAP
Original Assignee
University Of Tartu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Tartu filed Critical University Of Tartu
Publication of WO2012156473A2 publication Critical patent/WO2012156473A2/en
Publication of WO2012156473A3 publication Critical patent/WO2012156473A3/en

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B26HAND CUTTING TOOLS; CUTTING; SEVERING
    • B26DCUTTING; DETAILS COMMON TO MACHINES FOR PERFORATING, PUNCHING, CUTTING-OUT, STAMPING-OUT OR SEVERING
    • B26D3/00Cutting work characterised by the nature of the cut made; Apparatus therefor
    • B26D3/18Cutting work characterised by the nature of the cut made; Apparatus therefor to obtain cubes or the like
    • B26D3/185Grid like cutters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B26HAND CUTTING TOOLS; CUTTING; SEVERING
    • B26DCUTTING; DETAILS COMMON TO MACHINES FOR PERFORATING, PUNCHING, CUTTING-OUT, STAMPING-OUT OR SEVERING
    • B26D5/00Arrangements for operating and controlling machines or devices for cutting, cutting-out, stamping-out, punching, perforating, or severing by means other than cutting
    • B26D5/08Means for actuating the cutting member to effect the cut
    • B26D5/10Hand or foot actuated means
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B26HAND CUTTING TOOLS; CUTTING; SEVERING
    • B26DCUTTING; DETAILS COMMON TO MACHINES FOR PERFORATING, PUNCHING, CUTTING-OUT, STAMPING-OUT OR SEVERING
    • B26D3/00Cutting work characterised by the nature of the cut made; Apparatus therefor
    • B26D3/18Cutting work characterised by the nature of the cut made; Apparatus therefor to obtain cubes or the like
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B26HAND CUTTING TOOLS; CUTTING; SEVERING
    • B26DCUTTING; DETAILS COMMON TO MACHINES FOR PERFORATING, PUNCHING, CUTTING-OUT, STAMPING-OUT OR SEVERING
    • B26D5/00Arrangements for operating and controlling machines or devices for cutting, cutting-out, stamping-out, punching, perforating, or severing by means other than cutting
    • B26D5/08Means for actuating the cutting member to effect the cut
    • B26D5/18Toggle-link means
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B26HAND CUTTING TOOLS; CUTTING; SEVERING
    • B26DCUTTING; DETAILS COMMON TO MACHINES FOR PERFORATING, PUNCHING, CUTTING-OUT, STAMPING-OUT OR SEVERING
    • B26D7/00Details of apparatus for cutting, cutting-out, stamping-out, punching, perforating, or severing by means other than cutting
    • B26D7/06Arrangements for feeding or delivering work of other than sheet, web, or filamentary form
    • B26D7/0608Arrangements for feeding or delivering work of other than sheet, web, or filamentary form by pushers
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B26HAND CUTTING TOOLS; CUTTING; SEVERING
    • B26DCUTTING; DETAILS COMMON TO MACHINES FOR PERFORATING, PUNCHING, CUTTING-OUT, STAMPING-OUT OR SEVERING
    • B26D7/00Details of apparatus for cutting, cutting-out, stamping-out, punching, perforating, or severing by means other than cutting
    • B26D7/18Means for removing cut-out material or waste
    • B26D7/1818Means for removing cut-out material or waste by pushing out
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/178Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mechanical Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Forests & Forestry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention involves detection of differential expression of specific microRNAs (miRNAs) in certain biological/pathological conditions, and functional applications of miR-511, miR-193b,miR-99b and other listed miRNAs as markers and targets in cancer and immune system related diseases. The microRNAs are used as an expression modulation targets for influencing proliferative properties of a cell and/or immune functions of an organism.
PCT/EP2012/059186 2011-05-16 2012-05-16 A set of micrornas as markers and targets in cancer and immune system related diseases, methods for their application and a kit WO2012156473A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EEP201100037A EE201100037A (en) 2011-05-16 2011-05-16 Use of microRNAs as biomarkers and targets for influencing cell proliferative properties and a method and kit for detecting their expression level
EEP201100037 2011-05-16

Publications (2)

Publication Number Publication Date
WO2012156473A2 WO2012156473A2 (en) 2012-11-22
WO2012156473A3 true WO2012156473A3 (en) 2013-03-07

Family

ID=45937266

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/059186 WO2012156473A2 (en) 2011-05-16 2012-05-16 A set of micrornas as markers and targets in cancer and immune system related diseases, methods for their application and a kit

Country Status (2)

Country Link
EE (1) EE201100037A (en)
WO (1) WO2012156473A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106957894A (en) * 2016-01-11 2017-07-18 中国医学科学院肿瘤医院 MicroRNA molecule express spectra is used to predict the purposes that brain transplantation of non small cell Lung shifts risk
CN107137701B (en) * 2017-05-07 2020-07-14 山东兴瑞生物科技有限公司 Gene target and inhibitor for improving anti-liver cancer effect of DC vaccine and DC tumor vaccine
CN108125976B (en) * 2017-12-29 2020-07-31 唐山市人民医院 Molecular marker miR-4270 for predicting lung cancer brain metastasis and application thereof in medicines and diagnostic kits
CN111053789A (en) * 2019-11-26 2020-04-24 湖南营养树生物科技有限公司 Methods and compositions for modulating the immune system

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006028967A2 (en) * 2004-09-02 2006-03-16 Yale University Regulation of oncogenes by micrornas
WO2006137941A2 (en) * 2004-11-12 2006-12-28 Ambion, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
WO2010056737A2 (en) * 2008-11-11 2010-05-20 Mirna Therapeutics, Inc. Methods and compositions involving mirnas in cancer stem cells
WO2010129919A1 (en) * 2009-05-08 2010-11-11 Research Development Foundation Mirna expression in allergic disease
WO2011025919A1 (en) * 2009-08-28 2011-03-03 Asuragen, Inc. Mirna biomarkers of lung disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004032196A1 (en) 2004-07-02 2006-02-02 Strasser, Wolfgang, Dr.med. Test kit and pressure-sensitive adhesive tape for a cytological examination of the skin surface
US9394538B2 (en) 2008-05-07 2016-07-19 Shi-Lung Lin Development of universal cancer drugs and vaccines
EP2295598A4 (en) 2008-05-07 2013-06-12 Univ Sapporo Medical Method and kit for detection of cancer, and therapeutic agent for cancer
ITMI20091538A1 (en) 2009-09-07 2011-03-08 Istituto Naz Di Genetica Mole Colare Ingm PROFILES OF EXPRESSION OF MICRO-RNA IN THE PERIPHERAL BLOOD OF PATIENTS WITH HEPATOCARCINOMA OR HEPATIC CIRROSIS AND THEIR USES

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006028967A2 (en) * 2004-09-02 2006-03-16 Yale University Regulation of oncogenes by micrornas
WO2006137941A2 (en) * 2004-11-12 2006-12-28 Ambion, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
WO2010056737A2 (en) * 2008-11-11 2010-05-20 Mirna Therapeutics, Inc. Methods and compositions involving mirnas in cancer stem cells
WO2010129919A1 (en) * 2009-05-08 2010-11-11 Research Development Foundation Mirna expression in allergic disease
WO2011025919A1 (en) * 2009-08-28 2011-03-03 Asuragen, Inc. Mirna biomarkers of lung disease

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CEPPI M ET AL.: "MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, vol. 106, 24 February 2009 (2009-02-24), pages 2735 - 2740, XP002681809 *
FULCI V ET AL.: "Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia", BLOOD, vol. 109, 1 June 2007 (2007-06-01), pages 4944 - 4951, XP002681810 *
KIM T H ET AL.: "Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours", HISTOPATHOLOGY, vol. 57, 2010, pages 734 - 743, XP002681808 *
LODISH H F ET AL.: "Micromanagement of the immune system by microRNAs", NATURE REVIEWS IN IMMUNOLOGY, vol. 8, 2008, pages 120 - 130, XP002681811 *
MATTES JOERG ET AL: "Regulation of microRNA by antagomirs: a new class of pharmacological antagonists for the specific regulation of gene function?", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, AMERICAN LUNG ASSOCIATION, NEW YORK, NY, US, vol. 36, no. 1, 1 January 2007 (2007-01-01), pages 8 - 12, XP009086371, ISSN: 1044-1549, DOI: 10.1165/RCMB.2006-0227TR *
SHAO W ET AL: "Combined Application of Blocking Antibodies and MicroRNA Interference in Inhibiting CD44 Expression", TRANSPLANTATION PROCEEDINGS, ELSEVIER INC, ORLANDO, FL; US, vol. 42, no. 7, 1 September 2010 (2010-09-01), pages 2777 - 2781, XP027272931, ISSN: 0041-1345, [retrieved on 20100909] *
SHEEDY F J ET AL: "Adding fuel to fire: microRNAs as a new class of mediators of inflammation", ANNALS OF THE RHEUMATIC DISEASES, BRITISH MEDICAL ASSOCIATION, LONDON, GB, vol. 67, no. Suppl 3, 1 December 2008 (2008-12-01), pages 11150 - 11155, XP009122257, ISSN: 0003-4967, DOI: 10.1136/ARD.2008.100289 *
TAGANOV KONSTANTIN D ET AL: "NF-.kappa.B-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 103, no. 33, 15 August 2006 (2006-08-15), pages 12481 - 12486, XP002544549, ISSN: 0027-8424, DOI: 10.1073/PNAS.0605298103 *
TSEREL L ET AL.: "MicroRNA expression profiles of human blood monocyte-derived dendritic cells and macrophages reveal miR-511 as putative positive regulator of Toll-like receptor 4", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 286, no. 30, 29 July 2011 (2011-07-29), pages 26487 - 26495, XP002681812 *

Also Published As

Publication number Publication date
WO2012156473A2 (en) 2012-11-22
EE201100037A (en) 2012-12-17

Similar Documents

Publication Publication Date Title
WO2012094492A3 (en) Combinatorial dna taggants and methods of preparation and use thereof
EP3008201A4 (en) Methods, kits, and systems for multiplexed detection of target molecules and uses thereof
WO2012083969A3 (en) Microrna for diagnosis of pancreatic cancer
MX356625B (en) Oligonucleotides for making a change in the sequence of a target rna molecule present in a living cell.
WO2009111643A3 (en) Microrna markers for recurrence of colorectal cancer
AU2013216320A8 (en) C10RF32 Antibodies, And Uses Thereof For Treatment Of Cancer
IN2015DN01300A (en)
WO2013101902A3 (en) Chromophoric polymer dots with narrow-band emission
WO2014028429A3 (en) Enzymes and polymerases for the synthesis of rna
WO2011113030A3 (en) Human cancer micro-rna expression profiles predictive of chemo-response
WO2013158309A3 (en) Non-disruptive gene targeting
WO2012056457A3 (en) Compositions and methods for activating expression by a specific endogenous mirna
WO2012068383A3 (en) ncRNA AND USES THEREOF
NZ704718A (en) Epcam aptamer for detection of cancer stem cells
WO2011094335A3 (en) Microrna signatures predicting responsiveness to anti-her2 therapy
AR093446A1 (en) ANTIHEMAGLUTININE ANTIBODIES AND METHODS OF USE
WO2012078558A3 (en) microRNAs AS NEW THERAPEUTIC TARGETS FOR THE PREVENTION AND/OR TREATMENT OF RETINOPATHY
WO2012107841A3 (en) Micro -rna biomarkers for identifying risk of and/or for diagnosing lung tumour and pharmaceutical compositions thereof
WO2011153431A3 (en) Peripheral blood sparc antibodies and uses thereof
BR112014032940A2 (en) Carbohydrate esters as gene expression inducers
WO2013177593A3 (en) Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies
WO2011097509A3 (en) Hypoxia-related gene signatures for cancer classification
EP3825416A3 (en) Gene expression profiles associated with sub-clinical kidney transplant rejection
EP3365679B8 (en) Methods of identifying an individual as to be treated by chemotherapy based on marker molecules and related uses
WO2012156473A3 (en) A set of micrornas as markers and targets in cancer and immune system related diseases, methods for their application and a kit

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12727322

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12727322

Country of ref document: EP

Kind code of ref document: A2